Related references
Note: Only part of the references are listed.Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.
Andreas Du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
Sanghoon Lee et al.
CELL REPORTS (2020)
Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma
Se Ik Kim et al.
CANCERS (2020)
Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells
Hannah L. Smith et al.
CANCERS (2020)
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Aline Talhouk et al.
CLINICAL CANCER RESEARCH (2020)
Orthogonal Proteomic Platforms and Their Implications for the Stable Classification of High-Grade Serous Ovarian Cancer Subtypes
Stefani N. Thomas et al.
ISCIENCE (2020)
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Hyoung Kim et al.
NATURE COMMUNICATIONS (2020)
Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma
Yingwei Hu et al.
CELL REPORTS (2020)
Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer
Jianbo Pan et al.
NATURE COMMUNICATIONS (2020)
Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability
Jason E. McDermott et al.
CELL REPORTS MEDICINE (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Postoperative recurrence of epithelial ovarian cancer patients and chemoresistance related protein analyses
Zhengmao Zhang et al.
JOURNAL OF OVARIAN RESEARCH (2019)
Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma
Dylan Z. Dieters-Castator et al.
CLINICAL CANCER RESEARCH (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Yong Fang et al.
CANCER CELL (2019)
A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer
Ruth Huettenhain et al.
MOLECULAR & CELLULAR PROTEOMICS (2019)
Quantitative analysis of the human ovarian carcinoma mitochondrial phosphoproteome
Na Li et al.
AGING-US (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andrea Varga et al.
GYNECOLOGIC ONCOLOGY (2019)
Proteome- wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors
Guang Song et al.
MOLECULAR & CELLULAR PROTEOMICS (2019)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
Andrew R. Clamp et al.
LANCET (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The Cancer Genome Atlas: Creating Lasting Value beyond Its Data
Carolyn Hutter et al.
CELL (2018)
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Allen W. Zhang et al.
CELL (2018)
Complex regulatory mechanisms mediated by the interplay of multiple post-translational modifications
Veronika Csizmok et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2018)
Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics
Jaime Prat et al.
HUMAN PATHOLOGY (2018)
Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry
Philipp Mertins et al.
NATURE PROTOCOLS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer
Fabian Coscia et al.
CELL (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review
Giuseppe Scaletta et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer
Daniel Kritsch et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
International patterns and trends in ovarian cancer incidence, overall and by histologic subtype
S. B. Coburn et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery
Denis Querleu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
Carlos Bais et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
High grade serous ovarian carcinomas originate in the fallopian tube
S. Intidhar Labidi-Galy et al.
NATURE COMMUNICATIONS (2017)
Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer
Chiara Francavilla et al.
CELL REPORTS (2017)
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
Carlos Bais et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference
M. A. Bookman et al.
ANNALS OF ONCOLOGY (2017)
Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins
Isa N. Cruz et al.
CANCER GENOMICS & PROTEOMICS (2017)
Notch3-Specific Inhibition Using siRNA Knockdown or GSI Sensitizes Paclitaxel-Resistant Ovarian Cancer Cells
Haeyoun Kang et al.
MOLECULAR CARCINOGENESIS (2016)
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Hui Zhang et al.
CELL (2016)
How to Select Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients With Stage IIIC or IV Ovarian Carcinoma
Ignace B. Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures
Kun-Hsing Yu et al.
JOURNAL OF PROTEOME RESEARCH (2016)
Mass-spectrometric exploration of proteome structure and function
Ruedi Aebersold et al.
NATURE (2016)
Proteogenomics connects somatic mutations to signalling in breast cancer
Philipp Mertins et al.
NATURE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status
F. Coscia et al.
NATURE COMMUNICATIONS (2016)
Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses
Katarzyna M. Terlikowska et al.
JOURNAL OF OVARIAN RESEARCH (2016)
Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics
Hong Qu et al.
ONCOTARGET (2016)
A quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines
Gaofeng Fan et al.
BIOCHEMICAL JOURNAL (2015)
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
Yu Yu et al.
CANCER CELL (2015)
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
Andres M. Poveda et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The CPTAC Data Portal: A Resource for Cancer Proteomics Research
Nathan J. Edwards et al.
JOURNAL OF PROTEOME RESEARCH (2015)
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Sean Kehoe et al.
LANCET (2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma
Noriko Yamaguchi et al.
TUMOR BIOLOGY (2015)
The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer
Qinghua Xi et al.
TUMOR BIOLOGY (2015)
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Ilirjana Bajrami et al.
CANCER RESEARCH (2014)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
Alison Backen et al.
CLINICAL CANCER RESEARCH (2014)
Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma
Samantha Cohen et al.
GYNECOLOGIC ONCOLOGY (2014)
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Jaime Prat
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry- based Assay Development Using a Fit- for- Purpose Approach
Steven A. Carr et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Proteogenomic characterization of human colon and rectal cancer
Bing Zhang et al.
NATURE (2014)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2013)
Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
Fiona Collinson et al.
CLINICAL CANCER RESEARCH (2013)
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
Suk-Joon Chang et al.
GYNECOLOGIC ONCOLOGY (2013)
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Thea Eline Hetland et al.
HUMAN PATHOLOGY (2013)
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Roel G. W. Verhaak et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Louise J. Barber et al.
JOURNAL OF PATHOLOGY (2013)
Design, Implementation and Multisite Evaluation of a System Suitability Protocol for the Quantitative Assessment of Instrument Performance in Liquid Chromatography-Multiple Reaction Monitoring-MS (LC-MRM-MS)
Susan E. Abbatiello et al.
MOLECULAR & CELLULAR PROTEOMICS (2013)
The Coming Age of Complete, Accurate, and Ubiquitous Proteomes
Matthias Mann et al.
MOLECULAR CELL (2013)
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
Noriyuki Katsumata et al.
LANCET ONCOLOGY (2013)
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Zhigang C. Wang et al.
CLINICAL CANCER RESEARCH (2012)
BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer
Rebecca Byler Dann et al.
GYNECOLOGIC ONCOLOGY (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
Euan A. Stronach et al.
CANCER RESEARCH (2011)
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Thea Eline Hetland et al.
HUMAN PATHOLOGY (2011)
2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report From the Fourth Ovarian Cancer Consensus Conference
Gavin C. E. Stuart et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin
Joon Tae Park et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mass spectrometry in high-throughput proteomics: ready for the big time
Tommy Nilsson et al.
NATURE METHODS (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois et al.
CANCER (2009)
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma
Terri A. Addona et al.
NATURE BIOTECHNOLOGY (2009)
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
Katy Milne et al.
PLOS ONE (2009)
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
Lilach Kleinberg et al.
HUMAN PATHOLOGY (2008)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer
Sokbom Kang et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2006)
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer
MG Kelly et al.
CANCER RESEARCH (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Frequency of symptoms of ovarian cancer in women presenting to primary care clinics
BA Goff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Share Paper
